- Home
- ALLT vs IMMP Comparison
ALLT vs IMMP Comparison
Compare ALLT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLT
- IMMP
- Stock Information
- Founded
- ALLT 1996
- IMMP 1987
- Country
- ALLT Israel
- IMMP Australia
- Employees
- ALLT N/A
- IMMP N/A
- Industry
- ALLT Telecommunications Equipment
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ALLT Telecommunications
- IMMP Health Care
- Exchange
- ALLT Nasdaq
- IMMP Nasdaq
- Market Cap
- ALLT 229.8M
- IMMP 211.1M
- IPO Year
- ALLT 2006
- IMMP N/A
- Fundamental
- Price
- ALLT $5.38
- IMMP $1.51
- Analyst Decision
- ALLT Buy
- IMMP Buy
- Analyst Count
- ALLT 1
- IMMP 2
- Target Price
- ALLT $13.00
- IMMP $8.50
- AVG Volume (30 Days)
- ALLT 422.9K
- IMMP 84.6K
- Earning Date
- ALLT 05-28-2025
- IMMP 05-02-2025
- Dividend Yield
- ALLT N/A
- IMMP N/A
- EPS Growth
- ALLT N/A
- IMMP N/A
- EPS
- ALLT N/A
- IMMP N/A
- Revenue
- ALLT $92,195,000.00
- IMMP $3,019,249.00
- Revenue This Year
- ALLT $6.43
- IMMP N/A
- Revenue Next Year
- ALLT $5.83
- IMMP $20.28
- P/E Ratio
- ALLT N/A
- IMMP N/A
- Revenue Growth
- ALLT N/A
- IMMP 24.11
- 52 Week Low
- ALLT $1.99
- IMMP $1.32
- 52 Week High
- ALLT $9.44
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- ALLT 45.34
- IMMP 40.62
- Support Level
- ALLT $5.49
- IMMP $1.44
- Resistance Level
- ALLT $5.94
- IMMP $1.56
- Average True Range (ATR)
- ALLT 0.43
- IMMP 0.12
- MACD
- ALLT 0.06
- IMMP 0.00
- Stochastic Oscillator
- ALLT 64.33
- IMMP 38.78
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. It has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.